Fes Tyrosine Kinase Promotes Survival and Terminal Granulocyte Differentiation of Factor-dependent Myeloid Progenitors (32D) and Activates Lineage-specific Transcription Factors*

Jynho Kim, Yoshiyasu Ogata, and Ricardo A. FeldmanDagger

From the Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201

Received for publication, November 27, 2002, and in revised form, February 11, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The c-fps/fes proto-oncogene encodes a 92-kDa protein-tyrosine kinase that is involved in myeloid cell development and function. We have recently shown that expression of an activated allele of Fes (Fesact) in monocyte precursors resulted in their differentiation into functional macrophages through the activation of lineage-specific transcription factors. We now report that this kinase also plays a role in the survival and terminal differentiation of granulocyte progenitors. The expression of Fesact in factor-dependent 32D cells prevented their apoptotic death after interleukin-3 removal, but Fesact-expressing cells remained factor-dependent for proliferation. Removal of interleukin-3 from the Fesact-expressing cells was followed by granulocytic differentiation in the absence of granulocyte colony-stimulating factor within 4-8 days. The differentiated cells had distinctive granulocyte morphology and there was up-regulation of CD11b, Gr-1, and late differentiation markers such as lactoferrin, suggesting that this kinase induced terminal granulocytic differentiation. Concomitantly, Fesact down-regulated the macrophage marker F4/80, suggesting that the biological activity of Fes was coordinated in a lineage-specific manner. Further analysis showed that Fesact caused activation of CCAAT/enhancer-binding protein-alpha and STAT3, two transcription factors that are involved in granulocyte differentiation. Our results provide evidence that Fes may be a key component of the granulocyte differentiation machinery, and suggest a potential mechanism by which this kinase may regulate granulocyte-specific gene expression.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The differentiation of myeloid progenitors into monocyte-macrophages and granulocytes is regulated by the combined action of microenvironmental signals and lineage-specific transcription factors (1). One of the transcription factors involved in granulocytic differentiation is CCAAT/enhancer-binding protein (C/EBP)1 alpha : the promoters of G-CSFR and other granulocytic genes contain binding sites for C/EBP-alpha (1, 2); C/EBP-alpha knockout mice have no mature neutrophils or eosinophils (3); and conditional expression of C/EBP-alpha alone can induce granulocytic differentiation in U937, HL-60, and 32D cells (4, 5). The importance of this transcription factor for normal myelopoiesis is underlined by the recent finding that a subset of acute myeloid leukemias exhibit heterozygous mutations in the C/EBP-alpha protein. This results in truncated C/EBP-alpha molecules, which act as dominant negative mutants and block the expression of C/EBP-alpha target genes (6). The mechanism of transcriptional activation of C/EBP-alpha is not well understood, but recent evidence suggests that it involves its phosphorylation on Ser through a Ras-dependent mechanism (7). Another transcription factor that has been implicated in granulocyte development is signal transducer and activator of transcription (STAT) 3 (8). STAT3 is also activated by phosphorylation. In response to stimulation by a number of cytokines, STAT3 is phosphorylated on tyrosine, and several tyrosine kinases including Jak, Fes, and Src family kinases have been shown to activate STAT3 (9-15).

The c-fps/fes proto-oncogene encodes a 92-kDa cytoplasmic protein-tyrosine kinase that is primarily expressed in vascular endothelial cells (16, 17), monocyte-macrophages and granulocytes (18-20). Expression studies with cloned fps/fes genes have provided considerable evidence that this kinase is involved in macrophage differentiation. The expression of human c-fps/fes in K562 erythroleukemia cells resulted in their differentiation to macrophage-like cells (21), whereas infection of avian bone marrow progenitors with v-fps/fes viruses led to macrophage differentiation without added M-CSF (22). More recently we reported that a gain-of-function allele of Fes (Fesact) was capable of inducing terminal macrophage differentiation of U937 cells and other monocyte progenitors. This was accompanied by activation of PU.1, a transcription factor that is essential for macrophage development, providing evidence that Fes may regulate macrophage maturation through activation of lineage-specific transcription factors (23).

Although much less is known about the biological role of Fes in granulocytes, this kinase is likely to be an important regulatory molecule in this cell type. Antisense inhibition of Fes expression during retinoic acid-induced granulocytic differentiation of HL60 cells leads to apoptosis (24), suggesting a role of this kinase in the survival of differentiating granulocytic cells. More recently, it was reported that both Fes and the Fes-related kinase Fer can be activated after cross-linking of high affinity Fc receptor (Fcepsilon RI) in mast cells (25). Thus, Fes and Fer may have overlapping functions in leukocytes.

To further investigate the possible functions of Fes in granulocytes we have introduced Fesact into 32D, an IL-3-dependent cell line that undergoes granulocytic differentiation in the presence of G-CSF (26, 27). These cells have a normal karyotype, are non-tumorigenic, and have characteristics of normal granulocyte progenitors. Therefore, they have been used extensively as a model to study the mechanisms involved in granulocytic differentiation. Here we report that expression of Fesact in 32D protected these cells from apoptosis after IL-3 withdrawal, and that this was followed by terminal granulocyte differentiation in the absence of G-CSF. We also found that Fesact expression caused the transcriptional activation of C/EBP-alpha and STAT3. Our results suggest that Fes kinase may contribute to the regulation of myeloid gene expression during granulopoiesis through the activation of specific transcription factors.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cells-- 32D and WeHi-3B cells (27) were obtained from Weiqun Li (Georgetown University, Washington, DC). 32D cells were grown in RPMI 1640 medium supplemented with 15% fetal bovine serum, 1% penicillin, 1% streptomycin, and 5% WeHi-3B conditioned medium as a source of murine IL-3. The amphotropic retroviral packaging cell line Phoenix ampho was grown as described (23). For differentiation with G-CSF, 32D cells were incubated with 20 ng/ml recombinant murine G-CSF for the indicated times in the absence of IL-3.

DNAs-- Human c-Fes and Fesact cDNAs, the IRES-GFP-containing retroviral vector MigR1, MigR1-c-Fes, MigR1-Fesact, and the pCEFL vector were previously described (23). Details of construction of pCEFL-Fesact are available upon request. Luciferase reporters containing a 4× tandemly repeated C/EBP-alpha element, a wild type G-CSFR promoter that spans bp -1324 to +67, and a mutant C/EBP-alpha G-CSFR promoter that has a mutation from bp -49 to -45, corresponding to the C/EBP-alpha binding site, were obtained from Daniel Tenen (Harvard Medical School, Boston, MA) (2). cDNA probes to lactoferrin, lysozyme, and myeloperoxidase were obtained from Alan Friedman (Johns Hopkins University, Baltimore, MD) (28). Northern blot analysis was carried out as we described (29).

Transfection and Infection-- The transfection of Phoenix ampho cells with retroviral constructs, virus production, and infection of 32D cells were carried out as described previously (23). 32D cells infected with MigR1-Fesact virus were selected by incubation without IL-3 for 2 days. After this time dead cells were removed by centrifugation in HistopaqueTM (Sigma). The live cells were then expanded by incubation in IL-3 medium for 2-5 days. To assess the biological properties of Fesact, the cells were again resuspended in medium without IL-3 and analyzed as described in the text.

For transient transfection analysis, 32D cells were transfected with 15 µg of total plasmid DNA by electroporation. Transfection efficiency was normalized using a cotransfected promoter-less renilla vector pRL-0 (Promega, Madison, WI). Transactivation of the luciferase-linked C/EBP-alpha element and G-CSFR promoter were assayed 16 h after transfection using a dual luciferase kit from Promega.

Flow Cytometry-- Flow cytometric analysis was carried out as previously described (23). For surface marker staining, we used Phycoerythrin-labeled antibodies against murine CD11b and Gr-1 (BD Pharmingen), and Phycoerythrin-labeled antibodies against F4/80 (Caltag Laboratories, Burlingame, CA).

Immunoprecipitation and Western Blot Analysis-- The preparation of cell lysates, immunoprecipitation, SDS-PAGE, and immunoblotting with specific antibodies were carried out as previously described (23). Monoclonal anti-Fes antibodies have been previously described (30). The antibodies to phosphotyrosine (PY99), C/EBP-alpha , STAT3, and IL-3Ralpha were purchased from Santa Cruz (Santa Cruz, CA). Antibodies to phospho-STAT3 (Y705) were purchased from Cell Signaling Technology (Beverly, MA).

Preparation of Nuclear Extract and Electrophoretic Gel Mobility Shift Assay (EMSA)-- The preparation of nuclear protein extracts and gel shift assays (EMSA) were carried out as previously described (23). The oligonucleotide sequences used were: C/EBP consensus (31), sense 5'-TGCAGATTGCGCAATCTGCA-3, antisense 5'-TGCAGATTGCGCAATCTGCA-3'; STAT3-SIE (sis-inducible element) (14), sense 5'-GTGCATTTCCCGTAAATCTTGTC-3', antisense, 5'-GACAAGATTTACGGGAAATGCAC-3'; PU.1-CD11b (32), sense 5'-CTTCTGCCTCCTACTTCTCCTTTTCTGGCCT-3', antisense, 5'-AGGCCAGAAAAGGAGAAGTAGGAGGCAGAAG-3'.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Constitutively Active Fes Protects 32D Cells from Apoptosis Induced by IL-3 Withdrawal-- To gain insight into the possible role of Fes in granulocyte development we expressed Fesact, a constitutively active form of Fes in 32D cells. The recently described Fesact is a chimera between human and avian fps/fes cognate genes in which part of the kinase domain of human c-fes was replaced with the corresponding region from avian v-fps (Fig. 1A). Fesact is isogenic and colinear with both human c-Fes and avian v-Fps (23). Fesact was introduced into 32D cells by retrovirus-mediated gene transfer using the IRES-GFP vector MigR1 (33). 32D cells were infected with MigR1, MigR1-c-Fes, or MigR1-Fesact viruses (Fig. 1A) in the presence of IL-3 and 2 days later, IL-3 was removed from the culture medium. The uninfected, vector-, and c-Fes-infected 32D cells underwent apoptosis within 2 days of IL-3 withdrawal, but about 30% of the Fesact-infected 32D cells survived without IL-3. All of the surviving cells were green fluorescent, indicating that only Fesact-expressing cells were protected from apoptosis (Fig. 1B). This enabled us to rapidly isolate a population where 100% of the cells expressed Fesact. In the absence of IL-3, Fesact-infected cells remained viable for several days but their cell numbers did not appreciably increase (Fig. 2, A and B). This indicated that Fesact promoted the survival of 32D cells deprived of IL-3 but had no significant mitogenic effect. In the presence of IL-3, uninfected and Fes-infected cells proliferated at the same rate (Fig. 2B). As shown in Fig. 3, Fesact had no significant effect on the levels of expression of IL-3 receptor, as determined by immunoblot analysis using antibodies directed against the alpha  subunit of IL-3 receptor.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic representation of Fesact and constructs used for retroviral-mediated gene transfer. A, Fesact was constructed by replacing a portion of the kinase domain of human c-Fes with the corresponding v-Fps sequence from avian Fujinami sarcoma virus. The details of construction of this chimera have been described (23). In the switched kinase region, avian c-Fps and FSV-v-Fps differ in six point mutations, and the percentage of amino acid homology between human c-Fes and avian v-Fps in this region is 88% (Ref. 23, and references therein). c-Fes and Fesact were subcloned into the MigR1 retroviral vector, which contains a GFP cassette downstream of IRES. These constructions have been described (23). B, 32D cells were infected with MigR1 or MigR1-Fesact viruses as described under "Materials and Methods." Two days later cells were resuspended in medium without IL-3 and cultured for another 2 days. Dead cells were removed by centrifugation in HistopaqueTM and the remaining MigR1-Fesact-infected live cells were observed under a fluorescence microscope. After 2 days without IL-3, no surviving uninfected or vector-infected cells were recovered. Magnification: ×40.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Growth curve and viability of Fesact-infected 32D cells. 32D cells infected with Fesact virus were isolated and expanded as described under "Materials and Methods." After expansion, Fesact-infected cells were cultured in the presence or absence of IL-3 for the indicated times. Viability was determined by trypan blue exclusion (A), and cell numbers were determined using a hemocytometer (B). Cell numbers and viability were also followed in 32D cultures grown in the presence or absence of IL-3, and in 32D cultures treated with G-CSF in the absence of IL-3.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Activated Fes does not affect the expression of IL-3 receptor. 32D cells were infected with MigR1-Fesact viruses and the cells were allowed to differentiate in the absence of IL-3 for 4 days after which time, the cells were lysed. Total cell lysates (25 µg) from control 32D cells (lane 1) and from Fesact-infected 32D cultures (lane 2) were analyzed by SDS-PAGE (8.5% gel) followed by immunoblotting (WB, Western blot) with specific antibodies to the alpha  subunit of IL-3 receptor. Numbers at the left indicate the position of Mr markers. The position of IL-3Ralpha is indicated by an arrow.

We conclude from these results that activated Fes protected 32D cells from apoptosis caused by IL-3 withdrawal. This was not secondary to a mitogenic effect because Fesact-expressing cells remained factor-dependent for proliferation.

Fesact Induces Granulocytic Differentiation in the Absence of G-CSF-- We then examined whether Fesact had any other biological activity in 32D cells. To this end, 32D cells were infected with Fesact followed by selection in the absence of IL-3 for 2 days. The surviving Fesact-infected population was then allowed to expand for 3 days by supplementing the culture medium with IL-3. No phenotypic changes were detectable at the end of this period. Because IL-3 suppresses the biological activity of G-CSF and may also interfere with that of Fesact, IL-3 was removed from the Fesact-infected population once again, and the cells were monitored for phenotypic changes. Remarkably, the Fesact-expressing cells differentiated into granulocytes (Fig. 4A, panels D1 and D2). Differentiation by Fes required IL-3 deprivation for a total of 4-8 days, including the initial selection step. These cells acquired a characteristic mature granulocyte morphology, namely smaller cell size and multilobulated nuclei. Control uninfected 32D cells treated with G-CSF displayed granulocyte morphology within 5 days, and at day 9 more cells showed typical nuclear fragmentation (Fig. 4A, panels B and C). The highly fragmented nuclei seen after 9 days in G-CSF were not readily observed in Fesact-expressing 32D cells, indicating that Fesact-induced differentiation was not as complete as that obtained with G-CSF. Nevertheless, the mature granulocyte type was found in about 20% of this Fesact-expressing population, whereas the rest exhibited intermediate or normal blast morphologies. By comparison, after 5 days in G-CSF-containing medium, about 30% of the treated 32D cells underwent terminal differentiation. IL-3 greatly suppressed both G-CSF- and Fesact-dependent granulocytic differentiation (data not shown). Essentially the same results were obtained whether the source of IL-3 used to propagate uninfected or Fesact-infected 32D cells was recombinant IL-3- or WeHi-conditioned medium. In the experiments described above, Fesact-infected cells were reincubated with IL-3 after the initial IL-3 deprivation step, before removing it again to allow completion of differentiation. The expansion phase in IL-3 was done to obtain enough cells for our biochemical analysis, but it was not necessary to observe Fes-dependent differentiation. If the IL-3 expansion step was omitted, the Fesact-expressing cells differentiated to the same extent as those that were expanded in IL-3 (Fig. 4A, panel D3).


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 4.   Fesact induces granulocyte differentiation of 32D cells. A, uninfected 32D cells kept in IL-3 (panel A), 32D cells treated with G-CSF for 5 (panel B) or 9 (panel C) days, and Fesact-infected 32D cells that were deprived of IL-3 for 4 days (panel D) were stained with May-Grünwald Giemsa. Three different microscopic fields for each group are presented (1-3). In panels D1 and D2 Fesact-expressing cells were expanded in IL-3 as indicated in the text, whereas panel D3 corresponds to Fesact-expressing cells that were differentiated without an IL-3 expansion phase. B, a portion of the cultures described in A, above, were analyzed for surface expression of CD11b, Gr-1, and F4/80 by flow cytometry using specific (solid bars) or isotype-matched antibodies (striped bars) as described under "Materials and Methods." The plots represent the mean fluorescence intensity for isotype-matched and specific antibodies.

Coordinate Up-regulation and Down-regulation of Granulocyte and Macrophage Markers by Fesact-- To further characterize the biological activity of Fesact, we analyzed the expression of differentiation markers in Fesact-infected versus control 32D cells. As shown in Fig. 4B, Fesact up-regulated the expression of the common myeloid marker CD11b and the granulocyte-specific marker Gr-1 by severalfold, whereas expression of the macrophage-specific marker F4/80 was down-regulated by this kinase (Fig. 4B). Treatment of control 32D cells with G-CSF for 5 days was more efficient than Fesact in inducing CD11b and Gr-1 expression, but G-CSF was slower than Fesact in down-regulating F4/80. Like G-CSF, Fesact induced the expression of lysozyme and lactoferrin, two markers of late granulocytic differentiation, whereas expression of the early marker myeloperoxidase was down-regulated by Fes (Fig. 5). Although the time kinetics of up- and down-regulation of lineage-specific markers by Fesact and G-CSF was slightly different, their overall biological activities on granulocytic differentiation were comparable.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 5.   Up-regulation of late granulocytic marker expression by Fesact. 32D cells infected with Fesact virus were deprived of IL-3 for the indicated times. Total RNA was extracted from Fesact-infected (lanes 3-4, 7-8, and 11-12), control 32D (lanes 1, 5, and 9), and 32D cells allowed to differentiate in the presence of G-CSF for 5 days (lanes 2, 6, and 10) as described under "Materials and Methods." The RNA was subjected to Northern blot analysis (upper panel) using probes specific for lactoferrin (lanes 1-4), lysozyme (lanes 5-8), and myeloperoxidase (lanes 9-12) as described under "Materials and Methods." The lower panel corresponds to an ethidium bromide stain of the loaded RNA, showing the position of 18 S rRNA.

We conclude from these results that Fesact is capable of regulating myeloid gene expression in a lineage-specific manner. The extent of differentiation by Fes was not as complete as that induced by G-CSF. This suggests that under physiological conditions, additional cooperating signals are required to complete the granulocyte differentiation program. Nevertheless, the remarkable biological activity of Fesact we observed suggests that Fes kinase may play a key role in granulopoiesis.

Fesact Activates STAT3 and C/EBP-alpha but Not PU.1-- Since Fesact was able to induce granulocyte differentiation, we examined whether this kinase activated transcription factors that are important for myeloid development (1). To this end, we carried out EMSA of nuclear extracts from Fesact-infected 32D cells. As shown in Fig. 6A, lanes 3-5, both G-CSF and Fesact induced DNA-binding activity of STAT3. This activity was competed out by excess unlabeled specific oligonucleotide, but not by a nonspecific oligonucleotide (Fig. 6A, lanes 6 and 7). The addition of anti-STAT3 antibodies to the EMSA reaction resulted in a band supershift (Fig. 6A, lane 8), confirming the presence of STAT3 in the DNA-binding complexes induced by Fes.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Fesact induces tyrosine phosphorylation and DNA-binding activity of Stat3. A, 32D cells infected with MigR1-Fesact viruses (lanes 4-8) were allowed to differentiate in the absence of IL-3 for the indicated times. Nuclear extracts were prepared from uninfected (lane 2), G-CSF-treated (lane 3), and infected 32D cultures (lanes 4-8), and STAT3 DNA-binding activity was assayed by EMSA as described under "Materials and Methods." Unlabeled, specific (S) STAT3-SIE (lane 6), or nonspecific (NS) PU.1-CD11b (lane 7) oligonucleotides were included in the EMSA for competition. Anti-STAT3 antibody was used for supershift (lane 8). Arrows and asterisk at the right indicate the positions of STAT3 and supershifted STAT3 complexes. B, total cell lysates prepared from a portion of the cultures described in A, above were analyzed by SDS-PAGE followed by immunoblotting (WB, Western blot) with anti-phospho-STAT3 (Y705) antibodies (upper panel). The membrane was stripped and reblotted with antibodies to STAT3 (lower panel).

Transcriptional activation of STAT3 requires its phosphorylation on Tyr-705 (15). Consistent with the results of our EMSA, Fesact induced the phosphorylation of STAT3 on Tyr-705, as determined by immunoblot analysis using phosphospecific antibodies (Fig. 6B, lanes 3 and 4). The phosphorylated species migrated as a doublet, which probably corresponds to STAT3-alpha and its spliced form STAT3-beta . Neither G-CSF treatment or Fesact expression had any detectable effect on the expression levels of STAT3 (Fig. 6B).

Fesact also induced binding of nuclear extracts to an oligonucleotide that is specific for C/EBP family members (Fig. 7). This band was competed out by excess unlabeled specific oligonucleotide, but not by a nonspecific oligonucleotide (Fig. 7A, lanes 6 and 7). G-CSF also induced DNA binding to this oligonucleotide (Fig. 7A, lane 3). Although the G-CSF- and Fes-induced complexes had slightly different electrophoretic mobilities, anti-C/EBP-alpha antibodies caused a supershift of both transcriptional complexes indicating that they contained C/EBP-alpha (Fig. 7A, lanes 8 and 9). Neither G-CSF treatment nor Fesact expression modified the expression levels of C/EBP-alpha (data not shown). Whether other C/EBP family members are also activated by Fes will require further analysis. As shown in Fig. 7B, the expression of Fesact in 32D cells had no detectable effect on the DNA binding activity of PU.1. We conclude from these results that in 32D cells, Fesact induced the formation of C/EBP-alpha and STAT3 DNA-binding complexes.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 7.   Fesact expression results in activation of C/EBP-alpha . A, nuclear lysates were prepared from sister cultures of the control (lane 2), G-CSF-treated (lanes 3 and 9), and Fesact-infected (lanes 4-8) 32D cells described in the legend to Fig. 6A. C/EBP-alpha DNA-binding activity was assayed by EMSA as described under "Materials and Methods." C/EBP (lane 6) and STAT3-SIE (lane 7) were used as specific and nonspecific oligonucleotides, respectively, for competition. Anti-C/EBP-alpha antibody was used for supershift (lanes 8 and 9). The arrow and asterisk at the right indicates the positions of C/EBP-alpha and supershifted C/EBP-alpha complexes. B, the nuclear lysates described in A were assayed for PU.1 DNA-binding activity. PU.1 (lane 6) and STAT3-SIE (lane 7) were used as specific and nonspecific oligonucleotides, respectively, for competition. Anti-PU.1 antibody was used for supershift (lane 8). The arrow and asterisk at the right indicates the positions of PU.1 and supershifted PU.1 complexes.

Fesact Transactivates C/EBP-alpha and G-CSFR Reporter Genes-- To further examine the ability of Fes to induce transcriptional activation of C/EBP-alpha , we analyzed whether Fesact was able to transactivate a minimal luciferase-linked promoter containing 4 tandem repeats of the C/EBP-alpha -binding site. As shown in Fig. 8, Fesact was able to transactivate this C/EBP-alpha element. Since C/EBP-alpha is essential for transcription of the G-CSFR gene (2, 34), we also examined whether Fesact would be able to transactivate the G-CSFR promoter. Fesact transactivated the G-CSFR promoter, but not a promoter with a mutation in the C/EBP-alpha site (Fig. 8). We conclude from these results that Fesact can induce terminal granulocytic differentiation and the transcriptional activation of C/EBP-alpha and STAT3.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   Fesact transactivates a C/EBP-alpha element and the G-CSF receptor promoter. A, 32D cells were transfected with a 4× tandemly repeated C/EBP-alpha element linked to a luciferase reporter together with pCEFL vector or pCEFL-Fesact, by electroporation. Cells were lysed 16 h after transfection, and luciferase activity was measured as described under "Materials and Methods." B, 32D cells were transfected with a luciferase-linked G-CSF receptor promoter or a mutant from which the C/EBP-alpha site was mutated, along with pCEFL vector or pCEFL-Fesact. Luciferase activity was measured as described in A.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In this paper we present evidence that Fes kinase can regulate lineage-specific gene expression during granulocytic differentiation. We also identified the transcription factors C/EBP-alpha and STAT3 as potential Fes targets, which may mediate the biological activity of this kinase.

Although 32D cells behave as granulocytic progenitors, these cells are still capable of differentiating along the monocyte/macrophage lineage. Introduction of another tyrosine kinase, M-CSF receptor, into 32D cells allowed them to undergo partial monocytic differentiation in the presence of M-CSF (35). Also, ectopic expression of the transcription factor EGR-1 enabled these cells to undergo macrophage differentiation by GM-CSF treatment (36). Since Fesact was an inducer of macrophage differentiation in monocyte progenitors (23), it was of interest to determine whether in 32D cells, Fesact would induce macrophage or granulocytic differentiation, or both. By contrast with M-CSFR, Fesact was not able to change the lineage commitment of 32D cells but completed their granulocyte differentiation program. The results of these and our previous studies in monocytic cells (23) suggest that Fes may be involved in regulating the completion of terminal granulocyte and macrophage differentiation rather than a lineage decision step.

How does Fes kinase contribute to the execution of alternative programs of myeloid gene expression? In 32D cells Fes activated STAT3 and C/EBP-alpha , two important regulators of granulocytic differentiation (3, 8, 37, 38). On the other hand, PU.1, a transcription factor that is essential for macrophage development but has a more limited role in granulopoiesis (5) was activated by Fesact in U937 monoblasts but not in 32D cells. These results suggest that Fes may select its targets according to the lineage commitment stage of the cells, and that Fesact may induce granulocyte differentiation at least in part through transcriptional activation of STAT3 and C/EBP-alpha . The mechanism of activation of these factors may involve direct or indirect phosphorylation by Fes. In Fesact-expressing 32D cells, STAT3 was phosphorylated on Tyr-705, an event known to cause its transcriptional activation (15). Whether Fes activation of C/EBP-alpha also involves the phosphorylation of this protein will have to be clarified in future experiments.

Fesact protected 32D cells from apoptosis upon IL-3 withdrawal. This was not due to a conversion of the cells to factor independence because without IL-3, Fesact-expressing cells were essentially not dividing. By contrast with Fesact, the expression of v-Src, v-Abl, or Bcr-Abl in 32D cells does not result in differentiation but in their conversion to factor-independence and oncogenic transformation (26, 39-41). Thus, among non-receptor tyrosine kinases, Fes has a unique ability to induce granulocytic differentiation in 32D cells.

The fact that in 32D cells, both Fesact and G-CSF activated C/EBP-alpha and STAT3 suggests that Fes kinase may have utilized elements of the G-CSF pathway to drive granulocytic differentiation. There were also other similarities between the biological activities of G-CSF and Fesact: the time courses of granulocytic differentiation induced by G-CSF and active Fes were similar; G-CSF and Fesact induced granulocytic differentiation without IL-3, but their biological activity was greatly diminished in the presence of this cytokine; and both G-CSF and Fesact protected cells from apoptosis after IL-3 removal. Future experiments will be aimed at clarifying the functional relation of Fes to G-CSF and other cytokines that regulate granulocyte development.

Considering the large body of evidence that Fes plays a role in myeloid cell development, the phenotype of Fes knockout mice is milder than expected. Hackenmiller et al. (42) reported that some of the Fes-/- mice were compromised in their innate immunity, had low numbers of B cells, and elevated numbers of macrophages and granulocytes. Fes-/- macrophages exhibited defects in cell adhesion and GM-CSF signaling, pointing to incomplete maturation of their myeloid compartment. However, targeting of the Fes locus using a different strategy did not reveal alterations in the macrophage or granulocyte populations (43). This low penetrance of the Fes-/- phenotype may be a result of functional redundancy. A possible candidate that may compensate for the loss of Fes is the ubiquitously expressed Fer/NCP94 kinase, which has the same overall structure as Fes (18, 19, 44, 45). It was recently reported that in mast cells, Fer and Fes were both activated by Fcepsilon RI cross-linking (25). Thus, Fes and Fer may have overlapping functions in mast cells and basophils. These observations are consistent with the idea that in leukocytes, Fer may partially compensate for the absence of Fes. In granulocytes, functional complementation between Src family kinases has masked the phenotypic consequences of deleting single members of the family. For instance, defects in adhesion-dependent degranulation of polymorphonuclear neutrophils were observed only after ablation of both Hck and Fgr kinases (46). And defects in the respiratory burst response were only observed in neutrophils from hck-/-/fgr-/-/lyn-/- triple knockout mice (47). Since myeloid development can be regulated by multiple pathways (1, 48), it is likely that in addition to Fer there may be other mechanisms capable of compensating for the absence of Fes. For these reasons, we believe that both loss- and gain-of-function genetic approaches will be required to elucidate the biological functions and mechanism of action of Fes.

The results presented in this paper suggest that Fes may play an important role in granulopoiesis. Our observation that C/EBP-alpha and STAT3 are activated by Fes during this process suggests a potential mechanism by which this kinase may contribute to the regulation of granulocyte-specific gene expression during myeloid development.

    ACKNOWLEDGEMENTS

We thank Alan Friedman (Johns Hopkins University) for myeloid marker cDNA probes and Daniel Tenen (Harvard Medical School) for C/EBP-alpha and G-CSFR luciferase reporters. The excellent technical assistance by Humayra Ali is greatly appreciated.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA55293.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 410-706-4198; Fax: 410-706-2129; E-mail: rfeldman@umaryland.edu.

Published, JBC Papers in Press, February 12, 2003, DOI 10.1074/jbc.M212118200

    ABBREVIATIONS

The abbreviations used are: C/EBP, CCAAT/enhancer-binding protein; STAT, signal transducers and activators of transcription; GM-CSF, granulocyte macrophage colony-stimulating factor; IL-3, interleukin-3; EMSA, electrophoretic mobility shift assay; GFP, green fluorescent protein; IRES, internal ribosome entry site.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Clarke, S., and Gordon, S. (1998) J. Leukocyte Biol. 63, 153-168[Abstract]
2. Smith, L. T., Hohaus, S., Gonzalez, D. A., Dziennis, S. E., and Tenen, D. G. (1996) Blood 88, 1234-1247[Abstract/Free Full Text]
3. Zhang, D. E., Zhang, P., Wang, N. D., Hetherington, C. J., Darlington, G. J., and Tenen, D. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 569-574[Abstract/Free Full Text]
4. Radomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., and Tenen, D. G. (1998) Mol. Cell. Biol. 18, 4301-4314[Abstract/Free Full Text]
5. Wang, X., Scott, E., Sawyers, C. L., and Friedman, A. D. (1999) Blood 94, 560-571[Abstract/Free Full Text]
6. Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., and Tenen, D. G. (2001) Nat. Genet. 27, 263-270[CrossRef][Medline] [Order article via Infotrieve]
7. Behre, G., Singh, S. M., Liu, H., Bortolin, L. T., Christopeit, M., Radomska, H. S., Rangatia, J., Hiddemann, W., Friedman, A. D., and Tenen, D. G. (2002) J. Biol. Chem. 277, 26293-26299[Abstract/Free Full Text]
8. McLemore, M. L., Grewal, S., Liu, F., Archambault, A., Poursine-Laurent, J., Haug, J., and Link, D. C. (2001) Immunity 14, 193-204[Medline] [Order article via Infotrieve]
9. Brizzi, M. F., Aronica, M. G., Rosso, A., Bagnara, G. P., Yarden, Y., and Pegoraro, L. (1996) J. Biol. Chem. 271, 3562-3567[Abstract/Free Full Text]
10. Nelson, K. L., Rogers, J. A., Bowman, T. L., Jove, R., and Smithgall, T. E. (1998) J. Biol. Chem. 273, 7072-7077[Abstract/Free Full Text]
11. Park, W. Y., Ahn, J. H., Feldman, R. A., and Seo, J. S. (1998) Cancer Lett. 129, 29-37[CrossRef][Medline] [Order article via Infotrieve]
12. Shimoda, K., Feng, J., Murakami, H., Nagata, S., Watling, D., Rogers, N. C., Stark, G. R., Kerr, I. M., and Ihle, J. N. (1997) Blood 90, 597-604[Abstract/Free Full Text]
13. Wen, Z., Zhong, Z., and Darnell, J. E., Jr. (1995) Cell 82, 241-250[Medline] [Order article via Infotrieve]
14. Yu, C. L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., and Jove, R. (1995) Science 269, 81-83[Medline] [Order article via Infotrieve]
15. Zhong, Z., Wen, Z., and Darnell, J. E., Jr. (1994) Science 264, 95-98[Medline] [Order article via Infotrieve]
16. Greer, P., Haigh, J., Mbamalu, G., Khoo, W., Bernstein, A., and Pawson, T. (1994) Mol. Cell. Biol. 14, 6755-6763[Abstract]
17. Hackenmiller, R., and Simon, M. C. (2002) Dev. Biol. 245, 255-269[CrossRef][Medline] [Order article via Infotrieve]
18. Feldman, R. A., Gabrilove, J. L., Tam, J. P., Moore, M. A., and Hanafusa, H. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 2379-2383[Abstract]
19. MacDonald, I., Levy, J., and Pawson, T. (1985) Mol. Cell. Biol. 5, 2543-2551[Medline] [Order article via Infotrieve]
20. Samarut, J., Mathey-Prevot, B., and Hanafusa, H. (1985) Mol. Cell. Biol. 5, 1067-1072[Medline] [Order article via Infotrieve]
21. Yu, G., Smithgall, T. E., and Glazer, R. I. (1989) J. Biol. Chem. 264, 10276-10281[Abstract/Free Full Text]
22. Carmier, J. F., and Samarut, J. (1986) Cell 44, 159-165[Medline] [Order article via Infotrieve]
23. Kim, J., and Feldman, R. A. (2002) Mol. Cell. Biol. 22, 1903-1918[Abstract/Free Full Text]
24. Manfredini, R., Grande, A., Tagliafico, E., Barbieri, D., Zucchini, P., Citro, G., Zupi, G., Franceschi, C., Torelli, U., and Ferrari, S. (1993) J. Exp. Med. 178, 381-389[Abstract]
25. Craig, A. W., and Greer, P. A. (2002) Mol. Cell. Biol. 22, 6363-6374[Abstract/Free Full Text]
26. Rovera, G., Valtieri, M., Mavilio, F., and Reddy, E. P. (1987) Oncogene 1, 29-35[Medline] [Order article via Infotrieve]
27. Valtieri, M., Tweardy, D. J., Caracciolo, D., Johnson, K., Mavilio, F., Altmann, S., Santoli, D., and Rovera, G. (1987) J. Immunol. 138, 3829-3835[Abstract/Free Full Text]
28. Friedman, A. D., Krieder, B. L., Venturelli, D., and Rovera, G. (1991) Blood 78, 2426-2432[Abstract]
29. Areces, L. B., Dello Sbarba, P., Jucker, M., Stanley, E. R., and Feldman, R. A. (1994) Mol. Cell. Biol. 14, 4606-4615[Abstract]
30. Jucker, M., McKenna, K., da Silva, A. J., Rudd, C. E., and Feldman, R. A. (1997) J. Biol. Chem. 272, 2104-2109[Abstract/Free Full Text]
31. Choi, B. H., Park, G. T., and Rho, H. M. (1999) J. Biol. Chem. 274, 2858-2865[Abstract/Free Full Text]
32. Pahl, H. L., Scheibe, R. J., Zhang, D. E., Chen, H. M., Galson, D. L., Maki, R. A., and Tenen, D. G. (1993) J. Biol. Chem. 268, 5014-5020[Abstract/Free Full Text]
33. Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., and Baltimore, D. (1998) Blood 92, 3780-3792[Abstract/Free Full Text]
34. Zhang, P., Iwama, A., Datta, M. W., Darlington, G. J., Link, D. C., and Tenen, D. G. (1998) J. Exp. Med. 188, 1173-1184[Abstract/Free Full Text]
35. Pierce, J. H., Di Marco, E., Cox, G. W., Lombardi, D., Ruggiero, M., Varesio, L., Wang, L. M., Choudhury, G. G., Sakaguchi, A. Y., Di Fiore, P. P., and Aaronson, S. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5613-5617[Abstract]
36. Krishnaraju, K., Nguyen, H. Q., Liebermann, D. A., and Hoffman, B. (1995) Mol. Cell. Biol. 15, 5499-5507[Abstract]
37. Shimozaki, K., Nakajima, K., Hirano, T., and Nagata, S. (1997) J. Biol. Chem. 272, 25184-25189[Abstract/Free Full Text]
38. Wang, Q. F., and Friedman, A. D. (2002) Blood 99, 2776-2785[Abstract/Free Full Text]
39. Cleveland, J. L., Dean, M., Rosenberg, N., Wang, J. Y., and Rapp, U. R. (1989) Mol. Cell. Biol. 9, 5685-5695[Medline] [Order article via Infotrieve]
40. Cortez, D., Reuther, G., and Pendergast, A. M. (1997) Oncogene 15, 2333-2342[CrossRef][Medline] [Order article via Infotrieve]
41. Kruger, A., and Anderson, S. M. (1991) Oncogene 6, 245-256[Medline] [Order article via Infotrieve]
42. Hackenmiller, R., Kim, J., Feldman, R. A., and Simon, M. C. (2000) Immunity 13, 397-407[Medline] [Order article via Infotrieve]
43. Zirngibl, R. A., Senis, Y., and Greer, P. A. (2002) Mol. Cell. Biol. 22, 2472-2486[Abstract/Free Full Text]
44. Feldman, R. A., Tam, J. P., and Hanafusa, H. (1986) Mol. Cell. Biol. 6, 1065-1073[Medline] [Order article via Infotrieve]
45. Hao, Q. L., Heisterkamp, N., and Groffen, J. (1989) Mol. Cell. Biol. 9, 1587-1593[Medline] [Order article via Infotrieve]
46. Mocsai, A., Ligeti, E., Lowell, C. A., and Berton, G. (1999) J. Immunol. 162, 1120-1126[Abstract/Free Full Text]
47. Pereira, S., Zhou, M., Mocsai, A., and Lowell, C. (2001) J. Immunol. 166, 4115-4123[Abstract/Free Full Text]
48. Zhang, P., Nelson, E., Radomska, H. S., Iwasaki-Arai, J., Akashi, K., Friedman, A. D., and Tenen, D. G. (2002) Blood 99, 4406-4412[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.